Novel Fluoropyrimidines: Improving the Efficacy and Tolerability of Cytotoxic Therapy

Current Cancer Drug Targets

Volumn 4, Issue 2, 2004, Pages 191-204

  Petty, Russell D ^a,c   Cassidy, J ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Cytotoxic Drugs; Fluropyrimidines; Oncogenes; Tumour Suppresser genes

Indexed keywords

5 ETHYNYLURACIL; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FLUOROURIDINE TRIPHOSPHATE; FOLINIC ACID; METHOTREXATE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; UFT;

ATAXIA; BONE MARROW SUPPRESSION; CELL CYCLE; CELL DEATH; COLORECTAL CARCINOMA; CYTOTOXICITY; DIARRHEA; DNA SYNTHESIS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME POLYMORPHISM; ERYTHEMA; FATIGUE; HUMAN; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; NYSTAGMUS; REVIEW; TUMOR SUPPRESSOR GENE; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; NEOPLASMS; PYRIMIDINES;

EID: 1542724504     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009043481533     Document Type: Review

References (138)

1. Heidelberger, C.; Chandari, N. K.; Dannenberg, P. et al., Fluorinated Pyrimidines: A New Class of Tumour Inhibitory Compunds. Nature 1957, 199, 663.
2. Peters, G. J.; Jansen, G. Antimetabolites, In Oxford Textbook of Oncology; Souhami R. L; Tannock I., Hohenberger R.; Horiot J. C. Eds.; Oxford University Press: Oxford UK, 2002, pp663-715
3. Moore, H. C. F.; Haller, D. G. Adjuvant therapy of Colon Cancer. Semin. Oncol. 1999, 26(5), 545-555.
4. Northover, J. M. A.; Arnott, S.; Jass, J. R.; Williams, N. S.; Colorectal Cancer. In Oxford Textbook of Oncology; Souhami RL; Tannock I; Hohenberger R; Horiot JC Eds.; Oxford University Press; Oxford UK, 2002, pp1545-1591.
5. Pinedo, H. M.; Peters, G. J. 5-Fluorouracil: Biochemistry and Pharmacology. J. Clin. Oncol. 1988, 6, 1653-1654.
6. Weckbecker, G. Biochemical Pharmacology and Analysis of Fluropyrimidines Alone and in Combination with Modulators. Pharmacol. 1991, 50, 367-424.
7. Houghton, J. A.; Houghton, P. J. Elucidation of Pathways of 5-Flourouracil Metabolism in Xenografts of Human Colorectal Adenocarcinoma. Eur. J. Can. Clin. Oncol. 1983, 19, 807-815.
8. Ho, D. H.; Townsend, L.; Luna, M. L.; Bodey, G. P. Distribution and Inhibition of Dihydrouracil Dehydrogeenase Activities in Human Tissues Using 5-fluororuacil as a Substrate. Anticancer Res. 1986, 6, 781-784.
9. Tjaden, U. R.; De Bruijn, E. A. Chromatographic Analysis of Anticancer Drugs. J. Chrom. Biomed. Appl., 1990, 531, 235-294.
10. Presant, C. A.; Wolf, W.; Albright, M. J.; Servis, K. L.; Ring, R., III; Atkinson, D.; Ong, R. L.; Wiseman, C.; King, M.; Blayney, D. Tumour Trapping of 5-fluorouracil: In vivo 19F-NMR Spectroscoptic Pharmacokinetics in Tumour Bearing Humans and Rabbits. Proc. Natl. Acad. Sci. USA. 1990, 87, 492-496.
11. Presant, C. A. Association of Intratumoural Pharmacokinetics of Fluorouracil with Clinical Response. Lancet, 1994, 343, 1184-87.
12. Diasio, R. B.; Harris, B. E. Clinical Pharmacology of 5-Fluorouracil. Clin. Pharmacol. 1989, 6, 215-37.
13. Gamelin, E.; Boisdron-Celle, M.; Turcant, A.; Allain, P.; Robert, J.; Rapid, and Sensitive High Performance Liquid Chromatograpic Analysis of Halogenpyrimidines in Plasma. J. Chrom. 1997, 695, 409-416.
14. Ackland, S.P.; Garg, M.B.; Dunstan, R.H. Simultaneous determination of dihydrofluorouracil and 5-fluorouracil in plasma by high performance liquid chromatography. Anal. Biochem. 1997, 246, 79-85.
15. Woodcock, T. M.; Martin, D. S.; Damin, L. A. M.; Kemneny, N. E.; Young, C. W. Combination Clinical Trials with Thymidine and Fluorouracil: A Phase I and Clinical Pharmacological Evaluation. Cancer 1980, 45, 1135-1143.
16. Van Groeningen, C. J.; Pinedo, H. M.; Heddes, J. Pharmacokinetics of 5-flourouracil Assessed with a Sensitive Mass Spectrometric Method in Patients During a Dose Escalation Schedule. Cancer Res. 1988, 48, 6956-6961.
17. Myers, C. E. The Pharmacology of Fluoropyrimidines. Pharmacol. Rev. 1981, 33, 1-15.
18. Peters, G. J.; Van der Wilt, C. L.; Van Groeningen, C. J. Effect of Different Leucovorin Formulations on 5-fluorouracil Induced Thymidylate Synthase Inhibition in Colon Tumours and Normal Tissues from Patients in Relation to Response to 5-fluorouracil. In Pfleiderer W.; Rokos H. (Ed.). Chemistry and Biology of Pteridins and Folates (Proceedings of the 11th International Symposium). Berlin. Blackwell Science, 1997, pp.145-150.
19. Larsson, P-A.; Carlsson, G.; Gustavasson, B.; Graf, W.; Glimelius, B. Different Intravenous Administration Techniques for 5-flourouracil. Acta Oncol. 1996, 35,207-212.
20. Collins, J. M.; Dedrick, R. L.; King, F. G.; Speyer, J. L.; Myers, C. E. Non-linear Pharmacokinetic Models for 5-fluorouracil in Man. Clin. Pharmacol. Ther. 1980, 28, 235-246.
21. Hedgie, G. D.; Sommadossi, J. D.; Cross, D. S.; Huster, W. J.; Diasio, R. D. Clinical Pharmacokinetics of 5-fluorouracil and its Metabolites in Plasma, Urine and Bile. Cancer Res. 1987, 46, 2203-2206.
22. Mcloed, H. J.; Sludden, J.; Murray, G. I.; Keenan, R. A; Davidson, A. I. ; Park, K.; Koruth, M.; Cassidy, J.; Characteristaion of Dyhydropyrimidine Dehyrogenase Acivity in Colorectal Tumours. Br. J. Cancer 1998, 77, 461-465.
23. Malet-Martino, M. C.; Martino, R.; Lopez, A. New Approach to Metabolism of 5′deoxy-5-fluorouridine in Humans with Fluorine-19NMR. Cancer Chem. Pharmacol. 1984, 13, 31-35.
24. Diasio, R. B.; Beavers, T. L.; Carpenter, J. T. Familial Deficiency of Dihydropyrimidine Dehydrogenase: Biochemical Basis for Familial Pyrimidinemia and Severe 5-fluorouracil-Induced Toxicity. J. Clin. Invest. 1988, 81, 47-51.
25. Katona, C.; Kralovanszky, J.; Rosta, A.; Pandi, E.; Fonyad, G.; Toth, K. ; Jeney, A. Putative Role of Dihyropyrimidine Dehydrogenase in the Toxic Side Effect of 5-fluorouracil in Colorectal Cancer Patients. Oncology, 1998, 55, 468-474.
26. Fety, R.; Rolland, F.; Barberi-Heyob, M.; Hardouin, A.; Campion, L. Clinical impact of Pharmacokinetically-guided Dose Adaption of 5-fluorouracil: Results from a Multicentric Randomized trial in patients with locally advanced head and neck carcinomas. Clin. Cancer Res. 1998, 4, 2039-2045.
27. Meta-Analysis Group in Cancer. Toxicity of Flourouracil in Patients with Advanced Colorectal Cancer: Effect of Administration Scheduleand Prognostic Factors. J. Clin. Oncol. 1998, 16, 3534-3541.
28. Meta-Analysis Group in Cancer. Efficacy of intravenous Continous Infusion of Fluorouracil Compared with Bolus Administration in Advanced Colorectal Cancer. J. Clin. Oncol. 1998, 16, 301-308.
29. Bissett, D.; Ahmed, F.; Mcloed, H.; Cassidy, J. Oral Fluorouropyrmidines in the Treatment of Colorectal Cancer. Clin. Oncol., 2000, 12, 240-245.
30. Leyland-Jones, B.; O'Dwyer P. Biochemical Modulation: Application of laboratory models to the clinic. Cancer Treat. Rep. 1986, 70, 219-229.
31. Swain, S. M.; Lippmann, M. E.; Egan, E. F.; Drake, F. G.; Steinberg, S. M.; Allegra, C. J.; Fluorouracil and High Dose Leucovorin in Previously Treated Patients with Metastatic Breast Cancer. J. Clin. Oncol. 1989, 7, 890-899.
32. Daneberg P. V.; Daneberg K. D. Effect of 5,10-Methylenetetrahydrofolate on the Dissociation of 5-Flouro-2-deoxyuridylate from Thymidyate Synthetase: Evidence for an Ordered Mechanism. Biochem. 1978, 17, 4018-4024.
33. Van der Wilt, C. L.; Pinedo, H. M.; De Jong, M.; Peters, G. J. Effect of Folate Diastereoisomers on the Binding of 5-fluroro-2-deoxyuridine-5-monophosphate to Thymydylate Synthetase. Biochem. Pharmaco. 1993, 45, 1177-1199.
34. Rustum, Y. F.; Cao, S.; Zhang, Z. Rationale for treatment design: biochemical modulation of 5-fluorouracil by leucovorin. Cancer 1998, 4, 12-18.
35. Houghton, J. A.; Torrance, P. M.; Radparvar, S.; Williams, L. G.; Houghton, P. J. Binding of 5-fluorodeoxyuridylate to Thymidylate Synthase in Human Colon Adenocarcinoma Xenographs. Eur. J. Cancer Clin. Oncol. 1986, 22, 505-510.
36. Clark, J. L.; Berger, S. H.; Mittelman, A.; Berger, F. G. Thymidylate Synthase Overproduction Gene Amplification in a Colon Tumour Resistant to Fluoropyrimidine cChemotherapy. Cancer Treat. Rep. 1989, 71, 261-265.
37. Cory, J. G.; Breland, J. C.; Carter, G. L. Effect of 5-fluorouracil on RNA Metabolism in Novikoff Hepatoma cells. Cancer Res. 1979, 39, 4905-4913.
38. Will, C. L.; Dolnick, B. J. 5-fluorouracil Augmentation of Dihydrofolate Reductase Gene Transcripts Containing Intervening Sequences in Methotrexate Resistant KB cells. Mol. Pharmacol. 1996, 29, 643-648.
39. Spiegelman, S.; Sawyer, R.; Nayak, R.; Ritzi, E.; Stolfi, R.; Martin, D. S. Improving the Anti-Tumour Efficacy of 5-fluorouracil by Increasing its Incorporation into RNA by Metabolic Modulation. Proc. Natl. Acad. Sci. (USA). 1980, 389, 4966-4970.
40. Houghton, J. A.; Houghton, P. J.; Wooten, R. S. Mechanism of Induction of the Gastrointestinal Toxicity in the Mouse by 5-fluorouracil, 5-fluororidine and 5-Fluoro-2′-deoxyuridine. Cancer Res. 1979, 39, 2406-2413.
41. Glazer, R. I.; Hartman, K. D. A. The Effect of 5-fluorouracil on the Synthesis and Methylation of Low Molecular Weight RNA in L1210 cells. Mol. Pharmacol. 1980, 17, 245-249.
42. Griffith, D. A.; Jarvis, S. M. Nucleotide and Nucleobase Transport Systems of Mammalian Cells. Biochimica. Biophysica. Acta. 1963, 73, 160-162.
43. Papamichael, D. The use of Thymidylate Synthetase Inhibitors in the Treatment of advanced Colorectal Cancer: Current Status. Oncologist 1999, 4, 478-487.
44. Canman, C. E.; Randany, E. H.; Parsels, L. A.; Davis, M. A.; Lawrence, T. S.; Maybaum, J. Induction of Resistance to Flurodeoxyuridine Cytotoxicity and DNA Damage in Human Tumour Cells by Expression of Escercichia coli. Cancer Res. 1994, 344, 2296-2298.
45. Sawyer, R. C.; Stolfi, R. I.; Martin, D. S.; Spiegelman, S. Incorporation of 5-fluorouracil into Murine Bone Marrow DNA in vivo. Cancer Res. 1984, 44, 1847-1851.
46. Houghton, J. A.; Morton, C. L.; Adkins, D. A.; Rahman, A. Locus of the Interaction among 5-fluorouracil, Leucovorin, and Interferon-alpha-2A in Colon Carcinoma Cells. Eur. J. Cancer 1997, 33, 471-478.
47. Ayasawa, D.; Shimizu, K.; Koyama, H.; Takeish, K. Seno, T. Accumulation of DNA Strand Breaks during Thymineless Death in Thymidylate Negative Mutants of Mouse FM3A cells. J. Biol. Chem. 1988, 258, 122448-12454.
48. Malumbres, M.; Barbacid, M. To Cycle or Not to Cycle: A Critical Decision in Cancer. Nat. Rev. Cancer 2001, 1, 222-231.
49. Leist, M.; Jaalletta, M. Four Deaths and a Funeral: From Caspases to aAlternative Mechanisms. Nat. Rev. Mol. Cell Biol. 2001, 2, 1-10.
50. Peeters, T.; Haller, D. Therapy for Early Stage Colorectal Cancer. Oncology, 1999, 13, 307-313.
51. Topham, C. A. Challenging the Definition of 'best clinical practice': The Impact of New and Ongoing studies. The Effective Management of Colorectal Cancer. Cunningham D.; Haller D.; Miles A.; (editors). London. Aesulapius Medical Press, 2000, pp17-36.
52. Lokich, J. J.; Ahlgren, J. D.; Gullo, J. J.; Phillips, J. A.; Fryer, J. G. A Prospective Randomised Comparison of Continous Infusion Fluorouracil with a Conventional bolus Schedule in Metastatic Colorectal Cancer: A Mid-Atlantic Oncology Program Study. J. Clin. Oncol. 1989, 7, 425-432.
53. Advanced Colorectal Cancer Meta-analysis Project Modulation of Fluorouracil by Leucovorin in Patients with Advanced Colorectal Cancer: Evidence in Terms of Response Rate. J. Clin. Oncol. 1992, 10, 896-903.
54. Clark, P.I.; Slevin, M.L.; Reznek, R.H.; Niederle, N.; Kurschel, E. Two Randomised Phase II Trials of Intermittent Intravenous versus Subcutaneous Alpha-2 interferon alone (trial I) and in Combination with 5-fluorouracil (trial 2) in Advanced Colorectal Cancer. Int. J. Colorectal Dis. 1987, 2, 26-29.
55. Kohne, C. H.; Harstrick, A.; Hiddeman, W.; Goldman, I. J. Modulation of 5-fluorouracil with Methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in Patients with Advanced Colorectal Cancer. Results of a Phase II study. Eur. J. Cancer 1997, 33, 1896-1899.
56. Herrmann, S. R.; Spehn, J.; Beyer, J. H.; von Franque, U.; Schmieder, A. ; Holzmann, K. Sequential Methotrexate and 5-fluorouracil: Improved Response Rate in Metastatic Colorectal Cancer. J. Clin. Oncol. 1984, 2, 591-594.
57. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of Randomised Trials Testing the Biochemical Modulation of Fluorouracil by Methatrexate in Metastatic Colorectal Cancer. J. Clin. Oncol. 1994, 12, 960-969.
58. Radparvar, S.; Houghton, P. J.; Houghton, J. A. Effect of Polyglutamylation of 5,10-methyltetrahydrofolate on the Binding of 5-fluoro-2′-deoxyuridylate to Thymidylate Synthase Purified from a Human Colon Adencarcinoma Xenograft. Biochem. Pharmacol. 1989, 38, 335-342.
59. Advanced Colorectal Cancer Meta-analysis Project. Modulation of Fluorouracil by Leucovorin in Patients with Advanced Colorectal Cancer; Evidence in Terms of Response Rate. J. Clin. Oncol. 1992, 10, 896-903.
60. De Gramont, A.; Bosset, J. F.; Milan, C.; Rougier, P.; Bouche, O.; Etienne, P. L.; Morva F.; Louvet C. Randomised Trial Comparing Monthly Low Dose Leucovorin and Fluorouracil Bolus with Bimonthly High Dose Leucovorin and Fluorouracil plus Continuous Infusion for Advanced Colorectal Cancer: A French Intergroup Study. J. Clin. Oncol. 1997, 15, 808-815.
61. International Multicentre Pooled Analysis of Colon cancer Trials (IMPACT). Lancet 1995, 345, 939-945.
62. O'Connell, M. J.; Laurie, J. A.; Kahn, M.; Fitzgibbons, R. J., Jr.; Erlichman, C.; Shepherd, L.; Moertel, C. G.; Kocha, W. I.; Pazdur, R.; Wieand, H. S.; Rubin, J.; Vukov, A. M.; Donohue, J. H.; Krook, J. E.; Figueredo, A. Prospectively Randomised Trial of Post-Operative Adjuvant Chemotherapy in Patients with High Risk Colon Cancer. J. Clin. Oncol. 1998, 16, 295-300.
63. Wolmark, N.; Rockette, H.; Mamounas, E.; Jones, J.; Wieand, S.; Wickerham, D. L.; Bear, H. D.; Atkins, J. N.; Dimitrov, N. V.; Glass, A. G.; Fisher E.R.; Fisher B. Clinical Trial to Assess the Relative Efficacy of Fluorouracil and Leucovorin, Flurouracil and Levimasole in Patients with Duke's B and C Carcinoma of the Colon: Results from the National Surgical Adjuvant Breast and Bowel Project C-04. J. Clin. Oncol. 1999, 17, 3533-3539.
64. International Multicentre pooled Analysis of B2 Colon Cancer Trials Investigators. Efficacy of adjuvant 5-fluorouracil and leucovorin in B2 colon cancer. J. Clin. Oncol. 1999, 17, 1356-1363.
65. Sumpter, K.; Hill M. No Treatment for the over 65s? Agreeing a Definition of Fit and Unfit for Chemotherapy. The Effective Management of Colorectal Cancer. Cunningham D.; Haller D.; Miles A.; (editors). London. Aesulapius Medical Press, 2000, pp75-86.
66. QUASAR Collabourative Group. Comparison of Flurouracil with Additional Levimasole, Higher Dose Folinic Acid, or Both as Adjuvant Therapy for Colorectal Cancer: A Randomised Trial. Lancet 2000, 355, 1588-1595.
67. Saini, A.; Norman, A. R.; Cunningham, D.; Chau, I.; Hill, M.; Tait, D.; Hickish, T.; Iveson, T.; Lofts F. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br. J. Cancer 2003, 88, 1859-1865.
68. Petty, R. D.; Samuel, L. M.; Cassidy, J. Adjuvant Treatment of Dukes's C Colorectal Cancer with 6 cycles of Modified DeGramont 5-Fluorouracil/Folinic Acid Produces Disease Free and Overall Survival Comparible to 6 months of Treatment. Br. J. Cancer 2002, 86, (Suppl. I), S52.
69. Liu, G.; Franssen, E.; Fitch, M. I.; Warner, E. Patient Preferences for Oral Versus Intravenous Palliative Chemotherapy. J. Clin. Oncol. 1997, 15, 110-115.
70. Judson, R.; Beale, P. J. A Human Capecitabine Excretion Balance and Pharmacokinetic Study after Administration of a Single Oral Dose of 14C-labelled Drug. Invest. New Drug. 1999, 17, 49-56.
71. Miwa, M.; Ura, M.; Nisida, M. Design of a Novel Oral Fluoropyrimidine Carbamate, Capecitabine which generates 5-flurouracil Selectively in Tumours by Enzymes Concentrated in Human Liver and Cancer Tissue. Eur. J. Cancer 1998, 34, 1274-1281.
72. Schuller, J.; Cassidy, J. Preferential Activation of Capecitabine in Tumour Following Oral Administration to Colorectal Cancer Patients. Cancer Chem. Pharmacol. 2000, 45, 291-297.
73. Van Cutsem, E.; Findlay, M.; Osterwalder, B.; Kocha, W.; Dalley, D.; Pazdur, R.; Cassidy, J.; Dirix, L.; Twelves, C.; Allman, D.; Seitz, J. F.; Scholmerich, J.; Burger, H. U.; Verweij J. Capecitabine, an Oral Fluropyrimodine Carbamate with Substantial Activity in Colorectal Cancer: Results of a Randomised Phase II Study. J. Clin. Oncol. 2000, 18, 1337-1345.
74. Twelves, C. Vision of the Future: Capecitabine. Oncologist 2001, 6(suppl 4), 35-39.
75. Hoff, P. M.; Ansari, R.; Batist, G. Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First Line Treatment in 605 patients with Metastatic Colorectal Cancer; Results of a Randomised Phase III study. J. Clin. Oncol. 2001, 19, 2282-2292.
76. Van Cutsem, E.; Twelves, C.; Cassidy, J.; Allman, D.; Bajetta, E.; Boyer, M.; Bugat, R.; Findlay, M.; Frings, S.; Jahn,; McKendrick, J.; Osterwalder, B. ; Perez-Manga, G.; Rosso, R.; Rougier, P.; Schmiegel, W. H. Oral Capecitabine Compared with Intravenous 5-Fluoruracil plus Leucovorin (Mayo Clinic regimen) in Patients with Metastatic Colorectal Cancer; Results of a Large Phase III study. J. Clin. Oncol. 2001, 19, 4097-4106.
77. Hoff, P. M. Capecitabine as First line Treatment for Colorectal Cancer: Integrated Results from 1207 Patients from 2 Randomised Phase II studies. On behalf of the Capecitabine CRC study Group. Annal. of Oncol. 2000, 11(suppl. 4), 60a.
78. Hoff, P. M.; Cassidy, J.; Schmoll, H.-J. The Evolution of Fluoropyrimidine Therapy: From Intravenous to Oral. Oncologist 2001, 6(suppl. 4), 3-11.
79. Cassidy, J.; Twelves, C. Effective Dose Modification Scheme for the Management of Toxicities with Capecitabine Therapy; Data from Metastatic Colorectal Cancer Phase II Trials. Capecitabine CRC study Group. Annal. Oncol. 2000, 11(suppl. 4), 62a.
80. El Sayed Y. M.; Sadee W. Metabolic Activation of R,S-I-(tetrahydro-2-furanyl)-5-Fluorouracil by Soluble Enzymes. Cancer Res. 1983, 43, 4309-4344.
81. Tuchman, M.; Ramnaiarine, M. L.; O'Dea, R. F. Effects of Uridine and Thymidine on the Degradation of 5-fluorouracil, Uracil and Thymine by rat liver Dihydropyrimidine Dehydrgenase. Cancer Res. 1985, 45, 5553-5556.
82. Yamamoto, J.; Toide, K.; Haruno, A.; Yoshimura, Y.; Unemi, N. General Pharmacological Properties of UFT, a New type of Anti-cancer Agent Consisting of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) and Uracil.: Pharmacological Analysis of the Combined Effect of FT and Uracil. Arzneimittelforshrung, 1981, 31, 1268-1278.
83. Pazdur, R.; Lassere, Y.; Rhodes, V.; Ajani, A.; Sugarman, S. M.; Patt, Y. Z.; Jones, D. V., Jr.; Markowitz, A. B.; Abbruzzese, J. L. Phase II Trial of Uracil plus Tegafur plus Oral Leucovorin: An Effective Oral Regimen in the Treatment of Metastaic Colorectal Carcinoma. J. Clin. Oncol. 1994, 12, 2296-2300.
84. Ota, K.; Taguchi, T. Report on the Nationwide Pooled Data and Cohort Investigation in UFT Phase II study. Cancer Chem. Pharmacol. 1988, 22, 333-338.
85. Carmichael, J.; Popiela, T.; Radstone, D.; Falk, S.; Borner, M.; Oza, A. ; Skovsgaard, T.; Munier, S.; Martin, C. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol, 2002, 20, 3617-3627.
86. Pazdur, R. Phase II study of UFT plus leucovorin in colorectal cancer. Oncology. 1997; 54 Suppl. 1:19-23.
87. Ahmed, F. Y.; Johnston, S. J.; Cassidy, J.; O'Kelly, T.; Binnie, N.; Murray, G. I.; van Gennip, A. H.; Abeling, N. G. Eniluracil Treatment Completely Inactivates DPD Activity in Colorectal Tumours. J. Clin. Oncol. 1999, 17, 2439-2445.
88. Baker, S. D.; Khor, S. P.; Adjei, A. A.; Doucette, M.; Spector, T.; Donehower, R.C.; Grochow, L. B.; Sartorius, S. E.; Noe, D. A.; Hohneker, J., A. ; Rowinsky, E. K. A Pharmacokinetic, Oral Bioavailability and Safety of Fluorouracil in Patients Treated with 776C85, an Activator of DPD. J. Clin. Oncol. 1996, 14, 3085-96.
89. Schilsky, R. L.; Hohneker, J.; Ratain, M. J.; Janisch, L.; Smetzer, L.; Lucas, V. S.; Khor, S. P.; Diasio, R.; Von Hoff, D. D.; Burris, H. A. Phase I Clinical and Pharmacologic Study of Eniluracil Plus Fluorouracil in Patients with Advanced Cancer. J. Clin. Oncol. 1998, 16, 1450-1457.
90. Schilsky, R. L.; Bukowski, R.; Burris, H., III; Hochster, H.; O'Rourke, M.; Wall, J. G.; Mani, S.; Bonny, T.; Levin, J.; Hohneker, J. A Multicenter Phase II Study of a Five-Day Regimen of Oral 5-Fluorouracil Plus Eniluracil with or without Leucovorin In Patients with Metastatic Colorectal Cancer. Ann. Oncol. 2000, 11, 415-420.
91. Schilsky, R. L.; Levin, J.; West, W. H.; Wong, A.; Colwell, B.; Thirlwell, M. P.; Ansari, R. H.; Bell, W. N.; White, R. L.; Yates, B. B.; McGuirt, P. V.; Pazdur, R. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J. Clin. Oncol. 2002, 20, 1519-1526.
92. Marsh, J. C.; Catalano, P.; Huang, J.; Graham, D. L.; Cornfeld, M. J.; O'Dwyer, P. J.; Benson, A. B., III. Eastern Cooperative Oncology Group Phase III trial (E4296) of Oral 5-Fluorouracil and Eniluracil as a 28-Day Regimen in Metastatic Colorectal Cancer. Clin Colorectal Cancer 2002, 2, 43-50
93. Malhon, N. F.; Lloyd, A. C. Cell Senescence and Cancer. Nat. Rev. Cancer 2001, 1, 203-212.
94. Petak, I.; Tillman, D. M.; Harwood, F. G.; Mihalik, R.; Houghton, J. A. Fas-dependent and Fas-independent Mechanisms of Cell death following DNA damage in human colon carcinoma cells. Cancer Res. 2000, 60, 2643-2650.
95. Petak, I.; Tillman, D. M.; Hougton, J. A. p53 Dependence of fas Induction and Acute Apoptosis in Response to 5-fluorouracil-leucovorin in Human Colon Carcinoma cell lines. Clin. Cancer Res. 2000, 6, 4432-4441.
96. Houghton, J. A.; Harwood, F. G.; Tillman, D. M. Thymineless Death in Colon Carcinoma Cells is Mediated via Fas Signalling. Proc. Natl. Acad. Sci USA 1987, 94, 8144-8149.
97. Suda, T.; Takahashi, T.; Golstein, P.; Nagata, S. Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the TNF family. Cell 1993, 75, 1169-1178.
98. Moller, P.; Koretz, K.; Leithauser, F.; Bruderlein, S.; Henne, C.; Quentmeier, A.; Krammer, P. H. Expression of APO-I (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium Intl. J. Cancer 1994, 57, 371-377.
99. Nagata, S. Apoptosis by Death factor. Cell 1997, 88, 355-365.
100. Askenazi, A.; Dixit, V. M. Death Receptors: Signalling and Modulation. Science 1998, 281, 1305-1308.
101. Muller, M.; Wilder, S.; Bannasch, D.; Israeli, D.; Lehlbach, K.; Li, W. M.; Friedman, S. L.; Galle, P. R.; Stremmel, R. W. Oren, M.; Krammer, P. H. p53 Activated the CD95 (APO-I/fas) Gene in Reponse to DNA Damage by Anticancer Agents. J. Exp. Med. 1998, 188, 2033-20445.
102. Brown, J. M.; Wouters, B. G. Apoptosis, p53 and Tumour cell Sensitivity to Anticancer Agents. Cancer Research 1999, 59, 1391-1399.
103. Rakkar, A. N. S.; Katoyse, Y.; Kim, M.; Craig, C.; Ohiri, E.; Li, Z.; Cown, K. H.; Seth, P. A. A Novel Adenoviral Vector Expressing Human fas/APO-I/CD95 Enhances p53 Mediated Apoptosis. Cell Death Differen. 1999, 6, 326-333.
104. Kroemer, G. The Proto-oncogene Bcl-2 and its Role in Regulating Apoptosis. Nat. Med. 1997, 3, 614-617.
105. Fisher, T. C.; Milner, A. E.; Gregory, C. D.; Jackman, A. L. Bcl-2 Modulation of Apoptosis Induced by Anticancer Drugs: Resistance to Thymidylate Stress is Independent of Classical Resistance Pathways. Cancer Res. 1993, 53, 3321-3326.
106. Knudson, C. M.; Korsmeyer S. J. Bcl-2 and Bax Function Independently to Regulate Cell Death. Nat. Gen. 1997, 16, 358-363.
107. Peters, G. J.; Van Triest, H. H. J.; Backus, C. M.; Van der Wilt, C. L.; Pinedo, H. M. Molecular Downstream Events and Induction of Thymidylate Synthase in Mutant and Wild Type p53 Colon Cancer Cell Lines after Treatment with 5-Fluorouracil and the Thymidylate Synthase Inhibitor Raltitrexed. Eur. J. Cancer 2000, 36, 916-924.
108. [107a] Ribic, C. M.; Sargent, D. J.; Moore, M. J.; Thibodeau, S. J.; French, A. J.; Goldberg, R. N.; Hamilton, S. R.; Laurent-Puig, P.; Gryfe, R.; Shepherd, L. E.; Tu, D.; Redston, M.; Gallinger S. Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. N. Engl. J. Med. 2003, 349, 247-57.
109. Sinicrope, F. A.; Ruan, S. B.; Cleary, K. R.; Stephens, L. C.; Lee, J. J.; Levin B. Bcl-2 and p53 Oncoprotein Expression during Colorectal Tumourigenesis. Cancer Res. 1995, 55, 237-241.
110. Ishitsuka, H. Capecitabine; Preclinical Pharmacology Studies. Invest. New Drugs 2000, 18, 343-354.
111. O'Shaughnessy, J.; Miles, D.; Vukelja, S.; Moiseyenko, V.; Ayoub, J. P.; Cervantes, G.; Fumoleau, P.; Jones, S.; Lui, W. Y.; Mauriac, L.; Twelves, C.; Van Hazel, G.; Verma, S.; Leonard, R. Superior Survival with Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients with Advanced Breast Cancer: Phase III Trial Results. J. Clin. Oncol. 2002, 20, 2812-2823.
112. Fujimoto-Ouchi, K.; Tanaka, Y.; Tominaga, T. Schedule Dependency of Antitumor Activity in Combination Therapy with Capecitabine/5′ -Deoxy-5-Fluorouridine and Docetaxel in Breast Cancer Models. Clin. Cancer Res. 2001, 7, 1079-1086.
113. Vasey, P. A.; McMahon, L. A Phase II Ttrial of Capecitabine in Relapsed Ovarian Cancer. Ann. Oncol. 2000, 11(supl 4), 84a.
114. Cartwright, T. H.; Cohn, A.; Varkey, J. A.; Chen, Y. M.; Szatrowski, T. P.; Cox, J. V.; Schulz, J. J. Phase II Study of Oral Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer. J. Clin. Oncol. 2002, 20, 60-164.
115. Hess, V.; Salzberg, M.; Borner, M.; Morant, R.; Roth, A. D.; Ludwig, C.; Herrmann, R. Combining Capecitabine and Gemcitabine in Patients with Advanced Pancreatic Carcinoma: A Phase I/II Trial. J. Clin. Oncol. 2003, 21, 66-68.
116. Petty, R. D.; Nicolson, M. C.; Skaria, S.; Sinclair, T. S.; Samuel, L. M. A Phase II Study of Mitomycin C, Cisplatin and Protracted infusional 5-Flurorouracil (MCF) in Advanced Pancreatic Carcinoma: Efficacy and Low Toxcity. Ann. Oncol. 2003, 14, 1100-1105.
117. Douillard, J. Y.; Cunningham, D.; Roth A. Irinotecan combined with Fluorouracil Compared with Fluorouracil Alone in the First Line Treatment of Metastatic Colorectal Cancer: A Multicentre Randomised Trial. Lancet 2000, 355, 1041-1047.
118. Giacchetti, S.; Perpoint, B.; Zidani R. et al., Phase III Multicentre Randomised Trial of Oxaliplatin Added to Chronomodulated 5-Fluorouracil-leucovorin as First line Treatment for Metastatic Colorectal Cancer Oxaliplatin. J. Clin. Oncol. 2000, 18, 136-147.
119. De Gramont, A.; Figer, A.; Seymour, M. Leucovorin and Fluorouracil with or without Oxaliplatin as First Line Treatment in Advanced Colorectal Cancer. J. Clin. Oncol. 2000, 18, 905-914.
120. Adam, R.; Avisar, E.; Ariche, A.; Giachetti, A.; Azoulay, D.; Castaing D.; Kunstlinger F.; Levi F.; Bismuth F.Five-Year Survival Following Hepatic Resection After Neoadjuvant Therapy for Nonresectable Colorectal [Liver] Metastases Ann. Surg. Oncol. 2001, 8: 347-353.
121. Bismuth, H.; Adam, R.; Levi, F.; Giachetti, A. Resection of Nonresectable Liver Metastases from Colorectal Cancer after Neoadjuvant Chemotherapy. Ann. Surg. 1996, 224, 509-520.
122. Giacchetti, S.; Perpoint, B.;. Zidani, R.; Le Bail, N.; Faggiuolo, R.; Focan, C.; Chollet, P.; Llory, J.; Letourneau, Y.; Coudert, B.; Bertheaut-Cvitkovic, F.; Larregain-Fournier, D.; Le Rol, A.; Walter, S.; Ada, R.; Misset J.; Lévi F. Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil-Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer. J. Clin. Oncol. 2000, 18, 136-147.
123. Scheithauer, W.; Kornek, G. V. Raderer, M.; Schull, B.; Schmid, K.; Kovats, E.; Schneeweiss, B.; Lang, F.; Lenauer, A.; Depisch, D. Randomized Multicenter Phase II Trial of Two Different Schedules of Capecitabine plus Oxaliplatin as First-line Treatment in Advanced Colorectal Cancer. J. Clin. Oncol. 2003, 21(7), 1307-1312.
124. Kerr, D. J. Capecitabine/irinotecan Combination Regimens in Colorectal Cancer. Oncology 2002 16(4 Suppl 3),27-9.
125. Diaz-Rubio, E.; Evans, T. R.; Tabemero, J.; Cassidy, J.; Sastre, J.; Eatock, M.; Bisset, D.; Regueiro, P.; Baselga, J. Capecitabine (Xeloda) in Combination with Oxaliplatin: a Phase I, Dose-escalation Study in Patients with Advanced or Metastatic Solid tumors. Ann. Oncol. 2002, 13(4):558-65.
126. Paik, S. Incorporating Genomics into the Cancer Clinical Trial Process. Sem. Oncol. 2001, 28, 305-309.
127. Fisher, B.; Bryant, J.; Wolmark, N.; Mamounas, E.; Brown, A.; Fisher, E. R.; Wickerham, D. L.; Begovic, M.; DeCillis, A.; Robidoux, A.; Margolese, R. G. ; Cruz, A. B., Jr.; Hoehn, J. L.; Lees, A. W.; Dimitrov, N. V.; Bear, H. D. Effect of Preoperative chemotherapy on Outcome of Women with Operable Breast Cancer. J. Clin. Oncol. 1998, 16, 2672-2685.
128. Horikoshi, T.; Danenberg, K. D.; Stadbauer, T. H. Quantitation of Thymidylate Synthease, Dihydrofolate Reductase, DT-diaphorase Gene Expression in Human tumours using Polymerase Chain Reaction. Cancer Res. 1992, 51, 108-116.
129. Johnston, P., G.; Fisher, E. R.; Rockette, H. E.; Fisher, B.; Wolmark, N.; Drake, J. C. The role of Thymidylate Synthease Expression in Prognosis and Outcome of Adjuvant Chemotherapy in Patients with Rectal Cancer. J. Clin. Oncol. 1994, 12, 2640-2647.
130. Lenz, H. J.; Leichman, C. G.; Danenberg, K. D.; Danenberg, P. V.; Groshen, S.; Cohen, H.; Laine, L.; Crookes, P.; Silberman, H.; Baranda, J.; Garcia, Y.; Li, J.; Leichman, L. Thymidylate Synthase mRNA Level in Adenocarcinoma of the Stomach: A Predictor for Primary Tumour Response and Overall Survival. J. Clin. Oncol. 1996, 14, 176-182.
131. Johnston, P. G.; Mick, R.; Recand, W. Thymidylate Synthase Expression and Response to Neoadjuvant Chemotherapy in Patients with Advanced Head and Neck Cancer. J. Natl. Cancer Inst. 1997, 89, 308-313.
132. Pestalozzi, B. C.; Peterson, H. F.; Gelber, R. D.; Goldhirsch, A.; Gusterson, B. A.; Trihia, H.; Lindtner, J.; Cortes-Funes, H.; Simmoncini, E.; Byrne, M. J.; Golouh, R.; Rudenstam, C. M.; Castiglione-Gertsch, M.; Allegra, C. J. Prognostic Importance of Thymidylate Synthase Expression in Early Breast Cancer. J. Clin. Oncol. 1997, 75, 903-907.
133. Etienne, M. C.; Cheradame, S.; Fischel, J. L.; Formento, P.; Dassonville, O.; Renee, N. Response to Fluorouracil Therapy in Cancer Patients: The role of Tumoural Dihydropyrimidine Dehydrogenase. J. Clin. Oncol. 1995, 13, 1663-1670.
134. Ishikawa, Y.; Kubota, T.; Otani, Y.; Watanabe, M.; Teramoto, T.; Kumai, K.; Takechi, T. Dihydropyrimidine Dehydrogenase Activity and mRNA Level may be Correlated to to the Antitumour Effect of 5-fluorouracil on Human Tumour Xenografts in Nude Mice. Clin. Cancer Res. 1999, 5, 883-889.
135. Salonga, D.; Danenberg, K. D.; Johnson, M.; Metzger, R.; Groshen, S.; Tsao-Wei, D. D.; Lenz, H. J.; Leichman, C. G.; Leichman, L.; Diasio, R. B.; Danenberg, P. V. Colorectal Tumours Responding to 5-fluorouracil Have Low Gene Expression Levels of Dihydropyrimidine Dehydrogenase, Thymidylate Synthease and Thymidine Phosphorylase. Clin. Cancer Res. 2000, 6, 1322-1327.
136. Newell, D. R.; McLeod, H.L.; Schullens H. N.; The Pharmacology of Anti-cancer Drugs. In Oxford Textbook of Oncology; Souhami R. L; Tannock I; Hoheriberger R.; Horiot J.C. Eds.; Oxford University Press 2002, pp623-638.
137. DeRisi, U. J.; Penland, L.; Brown, P. O.; Bittner, M. L.; Meltzer, P. S. ; Ray, M.; Chen, Y. Use of a cDNA Microarray to Analyse Gene Expression Patterns in Human Cancer. Nat. Gen. 1996, 14, 457-460.
138. Tilman, D. M.; Petak L.; Houghton J. A. Fas-dependent Component in 5-flourouracil/leucovorin-induced Cytotoxicity in Colon Carcinoma cells. Clin. Cancer Res. 1999, 5, 425-430.